{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-138419","form_type":"8-K","ticker":"ACET","cik":"0001720580","company_name":"Adicet Bio, Inc.","filed_at":"2024-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.358007+00:00","generated_at":"2026-05-29T01:43:11.165304+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Adicet Bio doses first patient in Phase 1 trial of ADI-270 for advanced clear cell renal cell carcinoma","bullets":["First patient dosed in Phase 1 trial of ADI-270, an allogeneic gamma delta 1 CAR T cell therapy, for metastatic/advanced ccRCC.","Phase 1 trial is multicenter, open-label, monotherapy; starting dose 3E8 CAR+ cells with option for second dose.","Company expects to report preliminary Phase 1 clinical data in the first half of 2025.","Preclinical data showed ADI-270 demonstrated tumor infiltration, resistance to immunosuppressive TME, and potent CAR/innate activity.","ccRCC is the most common kidney cancer; patients with advanced disease have limited treatment options and high unmet need."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-138419","json":"https://secwatch.observer/filing/0000950170-24-138419.json","markdown":"https://secwatch.observer/filing/0000950170-24-138419.md","text":"https://secwatch.observer/filing/0000950170-24-138419.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/0000950170-24-138419-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720580/000095017024138419/acet-20241219.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T01:43:11.165304+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}